[Recent advances in L-asparaginase studies].
We surveyed the progress of L-asparaginase studies for last ten years or so, on the progress and the present situation for its clinical application. At present, L-asparaginase is recognized as one of basic drugs for improvement of remission induction mainly in infant ALL and is being positively incorporated in the treatment of high-risk diseases such as intractable ALL and the myelogenous recurrence. L-asparaginase, an E. coli-derived protein preparation, has various side effects except bone marrow suppression. Immune responses caused by E. coli-derived protein preparation is accordingly a characteristic side effect of the L-asparaginase. For the purpose of avoiding this side effect, studies on immobilized enzymes and enzyme derivatives devoid of antigenicity are under progress.
Taguchi
T
T
Division of Oncologic Surgery, Research Institute for Microbial Diseases Osaka University.
D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy
D001215:Asparaginase